What do systematic reviews say?

Immune checkpoint inhibitors vs any first‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 393 participants
  Moderate

Immune checkpoint inhibitors vs any second‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 727 participants
  Low

Radical prostatectomy vs active monitoring

• Radical prostatectomy versus deferred treatment for localised prostate cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 856 participants
  Moderate

Tivozanib vs sorafenib (targeted agent versus targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 506 participants
  Low

Sunitinib vs everolimus (targeted agent versus targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 288 participants
  Low

Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 691 participants
  Low

Sunitinib vs IFN‐α (targeted agent versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 544 participants
  Moderate

Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 401 participants
  Low

Sunitinib vs atezolizumab (targeted therapy versus immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 157 participants
  Low

Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 394 participants
  Low

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 460 participants
  Moderate

Pazopanib vs placebo (targeted agent versus placebo)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 300 participants
  High

Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sorafenib vs sunitinib (targeted agent versus targeted agent)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Everolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sorafenib vs pazopanib (targeted agent versus targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Low